Splenic marginal zone lymphoma: Current knowledge and future directions

Oncology

Volumn 26, Issue 2, 2012, Pages 1-11

  Thieblemont, Catherine ^a   Davi, Frederic ^b   Noguera, Maria Elena ^a   Brière, Josette ^a   Bertoni, Francesco ^c   Zucca, Emanuele ^c   Traverse Glehen, Alexandra ^d   Felman, Pascale ^d   Berger, Françoise ^d   Salles, Gilles ^d   Coiffier, Bertrand ^d  

^a SAINT LOUIS HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CLADRIBINE; FLUDARABINE; PEGINTERFERON; RIBAVIRIN; RITUXIMAB;

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; PATHOGENESIS; REVIEW; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY;

EID: 84857082918     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol. 2009;27:267-85.
2. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon, France: International Agency for Research on Cance Press; 2008.
3. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950-6.
4. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev. 2005;19:39-51.
5. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41-7.
6. Silvestri F, Barillari G, Fanin R, et al. Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma. Ann Oncol. 1998;9:499-504.
7. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11:285-91.
8. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100:107-15.
9. Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18:346-50.
10. Hermine O, Lefrere F, Bronowicki J, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;11:89-94.
11. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95-103.
12. Morse HC, Kearney JF, Isaacson PG, et al. Cells of the marginal zoneorigins, function and neoplasia. Leuk Res. 2001;25:169-78.
13. Saadoun D, Boyer O, Trebeden-Negre H, et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2004;41:1031-7.
14. Bates I, Bedu-Addo G, Jarrett RF, et al. B-lymphotropic viruses in a novel tropical splenic lymphoma. Br J Haematol. 2001;112:161-6.
15. Boveri E, Arcaini L, Merli M, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol. 2009;20:129-36.
16. Traverse-Glehen A, Davi F, Ben Simon E, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica. 2005;90:470-8.
17. Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica. 2010;95:1792-6.
18. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99:1299-304.
19. Traverse-Glehen A, Verney A, Baseggio L, et al. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia. 2007;21:1821-4.
20. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120:759-64.
21. Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol. 2008;143:71-4.
22. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487-95.
23. Duong Van Huyen JP, Molina T, Delmer A, et al. Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol. 2000;24:1581-92.
24. Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
25. Traverse-Glehen A, Baseggio L, Callet-Bauchu E, et al. Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity? Br J Haematol. 2010;150:113-6.
26. Warsame AA, Aasheim HC, Nustad K, et al. Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly-and self-reactive antibodies with similar reactivity. Blood. 2011;118:3331-9.
27. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia. 2005;19:1818-23.
28. Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia. 1997;11:747-58.
29. Sole F, Salido M, Espinet B, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86:71-7.
30. Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116:1479-88.
31. Aggarwal M, Villuendas R, Gomez G, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol. 2009;22:206-15.
32. Vega F, Cho-Vega JH, Lennon PA, et al. Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes. Br J Haematol. 2008;216-26.
33. Bouteloup M, Verney A, Rachinel N, et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol. 2012;156:279-81.
34. Corcoran M, Mould S, Orchard J, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271-7.
35. Cuneo A, Bardi A, Wlodarska I, et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia. 2001;15:1262-7.
36. Jadayel D, Matutes E, Dyer M, et al. Splenic lymphoma with villous lymphocytes: analysis of bcl-1 rearrangements and expression of the cyclin D1 gene. Blood. 1994;83:3664-71.
37. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol. 1993;85:487-91.
38. Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117:1595-604.
39. oB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118:4930-4.
40. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol. 2005;23:6415-20.
41. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643-9.
42. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106:1831-8.
43. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma-a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268-76.
44. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468-73.
45. Chacon J, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648-54.
46. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127-31.
47. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 2000;14:573-5.
48. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125-35.
49. Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90:856-8.
50. Cervetti G, Galimberti S, Cecconi N, et al. Role of low-dose 2-CdA in refractory or resistant lymphoplasmacytic lymphoma. J Chemother. 2004;16:388-91.
51. Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:452-7.